Pfizer
Biosimilar developer, United States. 7 development products across 7 molecules: adalimumab, bevacizumab, filgrastim, infliximab, pegfilgrastim, rituximab, trastuzumab.
First approval in the Atlas: Jun 2010, Nivestim, filgrastim (EMA)
FDAproducts approved7
EMAproducts approved7
PMDAproducts approved4
HCproducts approved7
CDSCOproducts approved0
EDEproducts registered4
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Adalimumab | Abrilada / Amsparity PF-06410293 | Nov 2019 | Feb 2020 | · | Jan 2021 | · | · |
| Bevacizumab | Zirabev PF-06439535 | Jun 2019 | Feb 2019 | Jun 2019 | Jun 2019 | · | Dec 2020 |
| Filgrastim | Nivestym / Nivestim PF-06881893 | Jul 2018 | Jun 2010 | · | Apr 2020 | · | · |
| Infliximab | Ixifi / Zessly PF-06438179 (GP1111) | Dec 2017 | May 2018 | Jul 2018 | Dec 2021 | · | · |
| Pegfilgrastim | Nyvepria PF-06881894 | Jun 2020 | Nov 2020 | · | Oct 2020 | · | May 2024 |
| Rituximab | Ruxience PF-05280586 | Jul 2019 | Apr 2020 | Sep 2019 | May 2020 | · | Feb 2021 |
| Trastuzumab | Trazimera PF-05280014 | Mar 2019 | Jul 2018 | Sep 2018 | Aug 2019 | · | Apr 2020 |
Month shown is the first approval or registration of that product in that market.
Also holds or markets
Products developed by another company for which Pfizer is the licence holder or applicant in one or more markets.
| Molecule | Brand | Market | Holder or applicant | Approved | Developer |
|---|---|---|---|---|---|
| Epoetin alfa and zeta | Retacrit | EMA | Pfizer Europe MA EEIG | Dec 2007 | Norbitec (Stada and Hospira) |
| Epoetin alfa and zeta | Retacrit | FDA | Hospira Inc., a Pfizer Company | May 2018 | Norbitec (Stada and Hospira) |
| Infliximab | Inflectra | EMA | Pfizer Europe MA EEIG | Sep 2013 | Celltrion |
| Infliximab | Pfizer (INN only) | CDSCO | Pfizer Limited | Sep 2021 | Celltrion |
Chronology
- EMAJun 2010Nivestim, filgrastim
- FDADec 2017Ixifi, infliximab
- EMAMay 2018Zessly, infliximab
- PMDAJul 2018Infliximab BS [Pfizer], infliximab
- FDAJul 2018Nivestym, filgrastim
- EMAJul 2018Trazimera, trastuzumab
- PMDASep 2018Trastuzumab BS [Pfizer], trastuzumab
- EMAFeb 2019Zirabev, bevacizumab
- FDAMar 2019Trazimera, trastuzumab
- HCJun 2019Zirabev, bevacizumab
- PMDAJun 2019Bevacizumab BS [Pfizer], bevacizumab
- FDAJun 2019Zirabev, bevacizumab
- FDAJul 2019Ruxience, rituximab
- HCAug 2019Trazimera, trastuzumab
- PMDASep 2019Rituximab BS [Pfizer], rituximab
- FDANov 2019Abrilada, adalimumab
- EMAFeb 2020Amsparity, adalimumab
- EMAApr 2020Ruxience, rituximab
- EDEApr 2020Trazimera, trastuzumab
- HCApr 2020Nivestym, filgrastim
- HCMay 2020Ruxience, rituximab
- FDAJun 2020Nyvepria, pegfilgrastim
- HCOct 2020Nyvepria, pegfilgrastim
- EMANov 2020Nyvepria, pegfilgrastim
- EDEDec 2020Zirabev, bevacizumab
- HCJan 2021Abrilada, adalimumab
- EDEFeb 2021Ruxience, rituximab
- HCDec 2021Ixifi, infliximab
- EDEMay 2024Nyvepria, pegfilgrastim
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.